{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T19:46:42Z","timestamp":1793908002148,"version":"4.8.0"},"reference-count":58,"publisher":"Informa UK Limited","issue":"11","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Bioanalysis"],"published-print":{"date-parts":[[2026,7,24]]},"DOI":"10.1080\/17576180.2026.2715916","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:36:01Z","timestamp":1787067361000},"page":"1031-1039","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["From analytical similarity to clinical confidence: how regulatory evolution ensures comparable immunogenicity in streamlined biosimilar development"],"prefix":"10.1080","volume":"18","author":[{"given":"Sandra","family":"Ribes","sequence":"first","affiliation":[{"name":"Hexal AG (a Sandoz company)","place":["Holzkirchen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Rosenbaum","sequence":"additional","affiliation":[{"name":"Hexal AG (a Sandoz company)","place":["Holzkirchen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Hartmann","sequence":"additional","affiliation":[{"name":"Hexal AG (a Sandoz company)","place":["Holzkirchen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Allmannsberger","sequence":"additional","affiliation":[{"name":"Hexal AG (a Sandoz company)","place":["Holzkirchen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Poetzl","sequence":"additional","affiliation":[{"name":"Hexal AG (a Sandoz company)","place":["Holzkirchen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-025-00727-z"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2025.2507173"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.70334"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011931"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1484"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1017\/cts.2020.493"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/17576180.2025.2461373"},{"key":"e_1_3_5_10_1","unstructured":"MHRA. Guidance on the licensing of biosimilar products [internet]. UK: Medicines & Healthcare products Regulatory Agency; 2025 Feb 27. Available from: https:\/\/www.gov.uk\/government\/publications\/guidance-on-the-licensing-of-biosimilar-products\/guidance-on-the-licensing-of-biosimilar-products"},{"key":"e_1_3_5_11_1","unstructured":"U.S. Food and Drug Administration. Guidance for industry: scientific considerations in demonstrating biosimilarity to a reference product: updated recommendations for assessing the need for comparative efficacy studies. 2025 Oct. Available from: https:\/\/www.fda.gov\/media\/189366\/download"},{"key":"e_1_3_5_12_1","unstructured":"European Medicines Agency. Reflection paper on a tailored clinical approach in biosimilar development [internet]. Amsterdam: European Medicines Agency; 2026. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/other\/reflection-paper-tailored-clinical-approach-biosimilar-development_en.pdf-0"},{"key":"e_1_3_5_13_1","unstructured":"Guidance on information and submission requirements for biosimilar biologic drugs [internet]. Ottawa: Health Canada; 2026. Available from: https:\/\/www.canada.ca\/content\/dam\/hc-sc\/documents\/services\/drugs-health-products\/biologics-radiopharmaceuticals-genetic-therapies\/applications-submissions\/guidance-documents\/information-submission-requirements-biosimilar-biologic-drugs\/information-submission-requirements-biosimilar-biologic-drugs.pdf"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1179\/2047480615Z.000000000329"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40290-025-00583-w"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.3997"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40290-024-00525-y"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2022.832059"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-020-00422-1"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2020.09.006"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2785"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-023-00631-4"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.15225"},{"key":"e_1_3_5_24_1","article-title":"Workshop summary report: increasing the efficiency of biosimilar development programs - reevaluating the need for comparative clinical efficacy studies [internet]","volume":"13","author":"IPRP","year":"2024","unstructured":"IPRP. Workshop summary report: increasing the efficiency of biosimilar development programs - reevaluating the need for comparative clinical efficacy studies [internet]. Int Pharm Regulators Programme. 2024;13. https:\/\/admin.iprp.global\/sites\/default\/files\/2024-07\/IPRP_BWG_Final%20IPRP%20Scientific%20Workshop%20Summary%20Report_2024_0506.pdf","journal-title":"Int Pharm Regulators Programme"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.6165"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-025-00733-1"},{"key":"e_1_3_5_27_1","unstructured":"ICH concept paper: M18: framework for determining the utility of comparative efficacy studies in biosimilar development programs [internet]. Geneva: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use; 2025. Available from: https:\/\/database.ich.org\/sites\/default\/files\/ICH_M18_Final_Concept_Paper_MCEndorsed_2025_1119.pdf"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2023.2239405"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa074943"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2013.11.014"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/btpr.2640"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.22276"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/1298473"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12247-019-09423-2"},{"key":"e_1_3_5_35_1","unstructured":"ICH harmonised tripartite guideline Q5E: comparability of Biotechnological\/biological products subject to changes in their manufacturing process. 2004."},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1839"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2018.1421169"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202941"},{"key":"e_1_3_5_39_1","unstructured":"ClinicalTrials.gov. Single dose comparability study of New and current dupilumab drug products subcutaneously administered in healthy adults [internet]. Bethesda: Clinical Trials.gov; 2025. Available from: https:\/\/clinicaltrials.gov\/study\/nct05976386"},{"key":"e_1_3_5_40_1","unstructured":"Assessment report: entyvio procedure No. EMEA\/H\/C\/002782\/X\/0075 [internet]. Amsterdam: European Medicines Agency; 2023. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/entyvio-h-c-002782-x-0075-epar-assessment-report-variation_en.pdf"},{"key":"e_1_3_5_41_1","unstructured":"Assessment report: opdivo procedure No. EMEA\/H\/C\/002782\/X\/0132 [internet]. Amsterdam: European Medicines Agency; 2014. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/opdivo-h-c-003985-x-0132-epar-assessment-report-variation_en.pdf"},{"key":"e_1_3_5_42_1","unstructured":"Dupixent: procedural steps taken and scientific information after authorization [internet]. Amsterdam: European Medicines Agency; 2025. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/procedural-steps-after\/dupixent-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01601-2"},{"key":"e_1_3_5_44_1","unstructured":"U.S. Food and Drug Administration. Guidance for industry: immunogenicity assessment for therapeutic protein products [internet]. Rockville: U.S. Food & Drug Administration; 2014. Available from: https:\/\/www.fda.gov\/media\/85017\/download"},{"key":"e_1_3_5_45_1","unstructured":"European Medicines Agency. Guideline on immunogenicity assessment of therapeutic proteins [internet]. Amsterdam: European Medicines Agency; 2017. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-immunogenicity-assessment-therapeutic-proteins-revision-1_en.pdf"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-026-00792-y"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1414304"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio-2023-0152"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2021.1993522"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2019.01.015"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.915412"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0031483"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-016-9948-4"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1704045"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1723110"},{"key":"e_1_3_5_56_1","volume-title":"ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of rDNA origin guidance for industry","author":"US Food and Drug Administration","year":"2021","unstructured":"US Food and Drug Administration. ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of rDNA origin guidance for industry. Vol. 12. Silver Spring: Food & Drug Administration; 2021. https:\/\/www.fda.gov\/media\/107622\/download"},{"key":"e_1_3_5_57_1","unstructured":"Guideline on the development and manufacture of synthetic peptides [internet]. Amsterdam: European Medicines Agency; 2025. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-development-manufacture-synthetic-peptides_en.pdf"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-023-00852-z"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biotechadv.2025.108575"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.3389\/fddsv.2022.952326"}],"container-title":["Bioanalysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17576180.2026.2715916","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/17576180.2026.2715916","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17576180.2026.2715916","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:37:33Z","timestamp":1787837853000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17576180.2026.2715916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":58,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,7,24]]}},"alternative-id":["10.1080\/17576180.2026.2715916"],"URL":"https:\/\/doi.org\/10.1080\/17576180.2026.2715916","relation":{},"ISSN":["1757-6180","1757-6199"],"issn-type":[{"value":"1757-6180","type":"print"},{"value":"1757-6199","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ibio20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ibio20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-05-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}